Erasca, Inc. Files 8-K Report

TL;DR

Erasca filed a routine 8-K, no major news.

AI Summary

On October 24, 2024, Erasca, Inc. filed an 8-K report. The filing indicates no significant new events or material changes requiring immediate disclosure beyond standard reporting. The company's principal executive offices are located at 3115 Merryfield Row, Suite 300, San Diego, California.

Why It Matters

This 8-K filing serves as a standard disclosure for Erasca, Inc., confirming no major events occurred that necessitate immediate reporting to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no disclosed material events, indicating no immediate new risks.

Key Players & Entities

• Erasca, Inc. (company) — Registrant
• October 24, 2024 (date) — Date of Report
• 3115 Merryfield Row, Suite 300, San Diego, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ERAS Nasdaq Glo

Filing Documents

• eras-20241024.htm (8-K) — 45KB
• 0000950170-24-116856.txt ( ) — 161KB
• eras-20241024.xsd (EX-101.SCH) — 25KB
• eras-20241024_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On October 24, 2024, Erasca, Inc. (the Company) announced preliminary data from its SEACRAFT-1 Phase 1b trial in an oral presentation at the 36 th EORTC-NCI-AACR (ENA) Symposium. In the Phase 1b trial of naporafenib plus trametinib (MEKINIST ) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations, the preliminary clinical activity of naporafenib plus trametinib in the melanoma cohort include, as of the efficacy cutoff date*: 40% (4/10) response rate observed in the efficacy-evaluable patients with NRAS Q61X melanoma, including three confirmed partial responses and one unconfirmed partial response; the melanoma cohort in SEACRAFT-1 is generally representative of the patient population currently being enrolled in the pivotal SEACRAFT-2 trial 70% (7/10) of patients remained on treatment as of the data cutoff, including all four responders *Safety data cutoff date was September 3, 2024. Efficacy data cutoff date was September 5, 2024. Naporafenib plus trametinib has been generally well tolerated as of the safety cutoff date, with mostly low-grade adverse events in the majority of patients. The Company believes that the use of mandatory primary rash prophylaxis helped reduce the frequency and severity of skin toxicities, reduced drug discontinuation rate due to adverse events, and improved the observed tolerability as measured by the increased relative dose intensity, as compared to the prior clinical trials of naporafenib plus trametinib conducted by Novartis, which did not include the use of mandatory primary rash prophylaxis. The Company believes that the preliminary SEACRAFT-1 data reinforce the potential of the ongoing Phase 3 SEACRAFT-2 trial in patients with NRAS-mutant (NRASm) melanoma. The Company expects to read out randomized dose optimization data from Stage 1 of the SEACRAFT-2 Phase 3 trial in 2025.

Forward-Looking Statements

Forward-Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company's current beliefs and expectations and include, but are not limited to: the Company's expectations regarding the potential therapeutic benefits and safety profile of its product candidates, including naporafenib; and the planned advancement of the Company's development pipeline, including the anticipated timing of future data readouts for Stage 1 of the SEACRAFT-2 trial, and other upcoming development milestones. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company's business, including, without limitation: preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available; the Company's approach to the discovery and development of product candidates based on the Company's singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; the Company's dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of the Company's product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; regulatory developments in the United States and foreign countries; the Company's ability t

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Erasca, Inc. Date: October 24, 2024 By: /s/ Ebun Garner Ebun Garner, General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR